Statements (161)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:virus
|
| gptkbp:advocacy |
important for policy change
|
| gptkbp:affects |
immune system
|
| gptkbp:age_group |
affects all ages
|
| gptkbp:antiretroviral_drugs |
reduce viral load
|
| gptkbp:associated_with |
discrimination
stigma |
| gptkbp:campaigns |
increase awareness
|
| gptkbp:can_lead_to |
opportunistic infections
certain cancers |
| gptkbp:cause |
gptkb:AIDS
|
| gptkbp:cd4_count |
indicator of immune function
|
| gptkbp:clinical_trial |
ongoing for new treatments
|
| gptkbp:collaboration |
aim to reduce transmission
|
| gptkbp:collaborations |
between countries
|
| gptkbp:community_health |
worldwide
can be managed with treatment focus on prevention and treatment important for outreach part of the Sustainable Development Goals |
| gptkbp:community_impact |
millions infected
significant public health issue significant mortality |
| gptkbp:community_outreach |
essential for education
|
| gptkbp:community_support |
crucial for affected individuals
|
| gptkbp:cultural_influence |
influence stigma
|
| gptkbp:customs |
associated with promiscuity
affects mental health associated with discrimination associated with drug use associated with homosexuality |
| gptkbp:diagnosis |
blood tests
HIV test antibody tests viral load tests |
| gptkbp:discovered_by |
gptkb:1983
gptkb:Luc_Montagnier gptkb:Françoise_Barré-Sinoussi |
| gptkbp:diseases |
gptkb:virus
gptkb:Kaposi's_sarcoma gptkb:Hepatitis_B gptkb:Cytomegalovirus Tuberculosis opportunistic infections |
| gptkbp:educational_programs |
target at-risk populations
|
| gptkbp:financial_support |
impacted by diagnosis
|
| gptkbp:frequency |
at least once a year for high-risk individuals
recommended annually for high-risk groups every 3 months for those at high risk |
| gptkbp:funding |
increased over the years
global health initiatives |
| gptkbp:gender_differences |
prevalence varies by gender
|
| gptkbp:grooming_needs |
measured in copies per milliliter
|
| gptkbp:has_lore |
can live long with treatment
not a death sentence anymore not transmitted by casual contact |
| gptkbp:healthcare |
disparities exist
play a key role in management |
| gptkbp:historical_significance |
influenced social movements
changed public health policies led to increased funding for research affected healthcare systems impacted global health initiatives influenced healthcare access debates raised awareness of sexual health shaped community responses |
| https://www.w3.org/2000/01/rdf-schema#label |
HIV
|
| gptkbp:infected_population |
growing in some regions
|
| gptkbp:is_involved_in |
available for patients
|
| gptkbp:is_monitored_by |
important for tracking outbreaks
|
| gptkbp:is_recognized_as |
gptkb:1983
in the United States |
| gptkbp:is_tested_for |
home testing kits
rapid tests home tests antibody test home testing kits available rapid tests available viral load test |
| gptkbp:is_vulnerable_to |
none available
|
| gptkbp:legal_issue |
related to discrimination
|
| gptkbp:lifespan |
improved with treatment
|
| gptkbp:long-term_management |
necessary for health
|
| gptkbp:origin |
gptkb:simian_immunodeficiency_virus_(SIV)
likely from simian immunodeficiency virus |
| gptkbp:prevalence |
38 million people infected
millions of people infected |
| gptkbp:prevention |
gptkb:education
regular testing condom use needle exchange programs Pr EP |
| gptkbp:provides_guidance_on |
varies by country
updated regularly |
| gptkbp:public_awareness |
community outreach
education programs public health campaigns important for prevention treatment access testing initiatives education on transmission |
| gptkbp:research |
gptkb:gene_therapy
prevention strategies treatment advancements ongoing vaccine development functional cure studies long-acting injectable treatments |
| gptkbp:research_focus |
vaccine development
treatment advancements understanding transmission |
| gptkbp:responds_to |
gptkb:UNAIDS
funding for research WHO initiatives |
| gptkbp:social_determinants |
affect health outcomes
|
| gptkbp:social_issues |
discrimination laws exist
|
| gptkbp:symptoms |
fatigue
fever rash swollen lymph nodes muscle aches |
| gptkbp:transmission |
gptkb:blood
sexual contact blood transfusion sharing needles mother to child |
| gptkbp:treatment |
gptkb:post-exposure_prophylaxis_(PEP)
gptkb:immunotherapy improving quality of life protease inhibitors prevention of mother-to-child transmission post-exposure prophylaxis viral suppression antiretroviral drugs long-term management improved life expectancy preventing transmission integrase inhibitors long-acting injectables pre-exposure prophylaxis (Pr EP) entry inhibitors fusion inhibitors adherence is crucial non-nucleoside reverse transcriptase inhibitors (NNRTIs) nucleoside reverse transcriptase inhibitors (NRTIs) |
| gptkbp:treatment_adherence |
critical for effectiveness
|
| gptkbp:type |
gptkb:HIV-1
gptkb:HIV-2 |
| gptkbp:type_of |
gptkb:HIV-1
gptkb:HIV-2 |
| gptkbp:viral_suppression |
achievable with treatment
|
| gptkbp:bfsParent |
gptkb:Global_Fund
gptkb:virus gptkb:Freddie_Mercury gptkb:The_Elton_John_AIDS_Foundation gptkb:Division_of_HIV/_AIDS_Prevention gptkb:Magic_Johnson gptkb:Oncology gptkb:World_AIDS_Day gptkb:Sangamo_Therapeutics gptkb:Elton_John_AIDS_Foundation |
| gptkbp:bfsLayer |
4
|